Premium
Comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients
Author(s) -
Nyström C.,
Hällström T.
Publication year - 1987
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1987.tb02805.x
Subject(s) - maprotiline , reuptake inhibitor , reuptake , medicine , depression (economics) , antidepressant , serotonin uptake inhibitors , drug , drug treatment , serotonin , anesthesia , psychiatry , psychology , fluoxetine , anxiety , receptor , macroeconomics , economics
— Seventy‐five outpatients with major depressive disorder (RDC) were randomly referred to treatment with a dominant serotonin (5‐HT) reuptake blocker (zimeldine, 100 mg, b.i.d. n = 40) or a dominant noradrenaline (NA) reuptake blocker (maprotiline, 75 mg, b.i.d. n = 35). Seven patients on each drug were non‐responders after up to 4 weeks of treatment and were after a washout week crossed over to the other drug for up to another 8 weeks of treatment. There was a significant and similar improvement after 4 weeks of treatment with the second drug. After up to 8 weeks of treatment all patients but one in each group were much improved with the second drug. The existence of two biochemical subgroups of depression is discussed.